SavedAdd your journal

Journals / MN Kardiyoloji / 2006 / Cilt: 13 - Sayı: 1

Glycoprotein IIb/IIIa receptor antagonists in the setting of acute ST-segment elevation myocardial infarction

ST yükselmeli akut koroner sendromda glikoprotein IIb/IIa reseptör antagonistleri

Cenk CONKBAYIR
Yusuf ATMACA
Pages
79–83
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this ar­tic­le, it is aimed to evaluate the use of GP IIb/IIIa inhibitors in the setting of acute ST-Segment elevation MI.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Glycoprotein (GP) IIb/IIIa inhibitors have been extensively studied in the setting of percutaneous coronary in­ter­ven­ti­on (PCI) and in the management of non-ST-segment elevation miyocardial infarction (NSTEMI).
📊
Key Findings & Data:However, the use of GP IIb/IIIa inhibitors is less well established in the setting of acute ST-segment elevation MI (STEMI).
💡
Conclusion & Impact:In this ar­tic­le, it is aimed to evaluate the use of GP IIb/IIIa inhibitors in the setting of acute ST-Segment elevation MI.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Koroner hastalık · Miyokard enfarktüsü · İntegrin beta 3

Abstract

Glycoprotein (GP) IIb/IIIa inhibitors have been extensively studied in the setting of percutaneous coronary in­ter­ven­ti­on (PCI) and in the management of non-ST-segment elevation miyocardial infarction (NSTEMI). However, the use of GP IIb/IIIa inhibitors is less well established in the setting of acute ST-segment elevation MI (STEMI). In this ar­tic­le, it is aimed to evaluate the use of GP IIb/IIIa inhibitors in the setting of acute ST-Segment elevation MI.

Özet

Glikoprotein (GP) IIb/IIIa reseptör inhibitörlerinin, perkütan koroner girişimlerde ve ST yükselmesiz akut koroner sen­dromda (AKS) kullanılması bugüne dek yapılmış geniş kapsamlı çalışmalarla aydınlatılmıştır. Bunun yanında, ST-yükselmeli AKS’da, GP IIb/IIIa inhibitörlerinin kullanımı daha az aydınlatılmıştır. Bu yazıda, ST-yükselmeli AKS’da, GP IIb/IIIa inhibitörlerinin yeri anlatılmaya çalışılacaktır.

🔖

Cite This Article

CONKBAYIR, C., ATMACA, Y. (2006). Glycoprotein IIb/IIIa receptor antagonists in the setting of acute ST-segment elevation myocardial infarction. MN Kardiyoloji, Cilt: 13 - Sayı: 1, 79–83. https://ajindex.com/articles/299189

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Fuster V, Badimon L, Badimon JJ, et al. The pathogenesis of CAD and ACS. N Engl J Med 1992
  2. Kleiman NS, Ohman EM, Kereiakes DJ, et al. Profound platelet inactivation with 7E3 shortly after thrombolytic therapy for acute myocardial infarction: preliminary results of the TAMI-8 trial. Circulation 1991
  3. Ohman EM, Kleiman NS, Gacioch G, et al. Combined accelerated tissue-plasminogen activator and platelet glycoprotein llb////a integrin receptor blockade with integrilin in AMI: results of IMPACT-AMI. 4.PARADIGM Investigators. Combining thrombolysis with the platelet glycoprotein llb/llla inhibitor lamifiban: results of the platelet aggregation receptor antagonist dose investigation and reperfusion gain in myocardial infarction (PARADIGM) trial. J Am Coll Cardiol 1998
  4. Lincoff AM, Califf RM, Van de Werf F, et al. Mortality at 1 year with combination platelet glycoprotein llb/llla inhibition and reduced dose fibrynolytic therapy vs conventional fibrynolytic therapy for acute myocardial infarction: GUSTO V randomized trial. JAMA 2002
  5. Antman EM, Giugliano RP, Gibson CM, et al. Abciximab fascilitates the rate and extent of thrombolysis: results of the TIMI 14 trial. Circulation 1999
  6. Topol EJ, Ohman EM,for the SPEED Investigators. Trial of abciximab with and without low-dose reteplase for AMI: results of SPEED. Circulation 2000
  7. Brener SJ, Zeymer U, Adgey AA, et al. Eptifibatide and low-dose tissue plasminogen activator in acute Ml: the INTRO AMI trial. J Am Coll Cardiol 2002
  8. Van de Werf F, for the ASSENT-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractioned heparin: results of the ASSENT-3 trial. Lancet 2001
  9. Brener SJ, Barr LA, Burchenal JEB, et al. Randomized, placebo-controlled trial of platelet GP llb/llla blockade with primary angioplasty for AMI: results of RAPPORT. Circulation 1998
  10. Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty with stenting, with or without abciximab, in AMI: -esults of the CADILLAC trial. N ENGL J Med 2002
  11. Montalescot G, Barragan P, Wittenberg O, et al. Platelet GP IIb/llla inhibition with coronary stenting for AMI: results of the ADMIRAL trial. N Engl J Med 2001
  12. Neumann J, Kastrati A, Schmitt C, et al. Effect of GP llb/llla receptor blockade with abciximab on clinical and angiographic restenosis rate af